Table 2 Tocotrienol intake and risk of breast cancer-specific death/recurrence in women with early breast cancer and estrogen receptor-positive tumors receiving tamoxifen
| Â | Type of treatment received along with tamoxifen | |
|---|---|---|
| Â | Placebo (n= 120) | Tocotrienol (n= 120) |
Breast cancer-related death | Â | Â |
   Number of patients (n (%)) | 6 (5.0) | 2 (1.7) |
   Crude hazard ratio | 1.00 | 0.33 (95% CI, 0.07 to 1.61) |
   Adjusted hazard ratioa | 1.00 | 0.40 (95% CI, 0.08 to 2.05) |
Local/systemic recurrence of breast cancer | Â | Â |
   Number of patients (n (%)) | 20 (16.7) | 16 (13.3) |
   Crude hazard ratio | 1.00 | 0.80 (95% CI, 0.41 to 1.54) |
   Adjusted hazard ratioa | 1.00 | 0.84 (95% CI, 0.43 to 1.65) |